The preclinical program of our lead product APC148 is on-track and funded through 2022. Initial APC247 R&D data supported a patent application late 2021 and was an opportunity for applying for soft funding to start preclinical development. These activities will include chemical synthesis and scale-up, testing on resistant bacteria strains and a safety program in animals leading to the first study in humans.
Bacteria defend themselves against antibiotics by developing resistance enzymes destroying the antibiotics. Two enzyme families, serine-beta-lactamases (SBL) and metallo-beta-lactamases (MBL) are the most common. There are antibiotics on the market combining with SBL enzyme inhibitors, none combined with MBL enzyme inhibitors. The market is eagerly waiting for broad-spectrum beta-lactamase-inhibitors covering both SBLs and MBLs, and initial results with APC247 show that Adjutec is on the right track.
Nicolaj Weiergang, AdjuTec Pharma Chair of Board, comments “While our lead product APC148 is on-track and has a market opportunity by itself, we see a great upside for AdjuTec to complement our pipeline with the development of APC247. It covers a larger spectrum of resistant enzymes, diversifies company risk and increases the value creation. AdjuTec will continue to attract soft funding to its pipeline projects and expand on its core technology.”
About antimicrobial resistance (AMR) – https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance
AMR is a global health and development threat. It requires urgent multi-sectoral action in order to achieve the Sustainable Development Goals (SDGs). WHO has declared that AMR is one of the top 10 global public health threats facing humanity. Misuse of antimicrobials are the main drivers in the development of drug-resistant pathogens. Lack of clean water and sanitation and inadequate infection prevention and control promotes the spread of microbes, some of which can be resistant to antimicrobial treatment. The cost of AMR to the economy is significant. In addition to death and disability, prolonged illness results in longer hospital stays at intensive care units and isolate wards. In addition, there is a need for more expensive medicines and financial challenges for those impacted. Without effective antimicrobials, the success of modern medicine in treating and preventing infections during major surgery and cancer chemotherapy, can be jeopardized.
About AdjuTec Pharma
AdjuTec Pharma is a Company that is dedicated to developing and providing novel antibiotic resistance breakers to the global market. The Company technology offers a unique mechanism of action that inactivates bacterial defense enzymes and restores bacterial sensitivity to antibiotics. The Company lead product is APC148, a selective zinc chelator targeting bacteria metallo-ß-lactamase (MBL) enzymes. The technology is developed by Professor Pål Rongved and his group at Department of Pharmacy, University of Oslo. The Company is located at Oslo Cancer Cluster Innovation Park next to the Radium Hospital, Oslo.
For more information, please visit www.adjutecpharma.com
Please contact: info@adjutecpharma.com